Hannah K Betcher1,2, Catalina Montiel1, Crystal T Clark1,3. 1. Department of Psychiatry, Northwestern University Feinberg School of Medicine 676 N. St. Clair St. Ste 1000, Chicago, IL 60611, USA. 2. Mayo Clinic, Rochester, MN, USA. 3. Department of Obstetrics and Gynecology, Northwestern Feinberg School of Medicine, Chicago, IL, USA.
Abstract
PURPOSE OF REVIEW: Antipsychotics are frequently prescribed to women of childbearing age and are increasingly prescribed during pregnancy. A small, but growing, body of research on implications for pregnancy and infant outcomes is available to inform the risks and benefits of in utero exposure to antipsychotics. This review examines the existing published research on the use of common typical and atypical antipsychotics in pregnancy and the implications for pregnancy and infant outcomes. RECENT FINDINGS: The majority of studies do not show associations with major malformations and antipsychotic use in pregnancy, with the possible exception of risperidone. There is concern that atypical antipsychotics may be associated with gestational diabetes. Metabolic changes during pregnancy may necessitate dose adjustments. SUMMARY: In general, it is recommended that women who need to take an antipsychotic during pregnancy continue the antipsychotic that has been most effective for symptom remission. Further study on risperidone is needed to better understand its association with malformations and it is not considered a first-line agent for use during pregnancy.
PURPOSE OF REVIEW: Antipsychotics are frequently prescribed to women of childbearing age and are increasingly prescribed during pregnancy. A small, but growing, body of research on implications for pregnancy and infant outcomes is available to inform the risks and benefits of in utero exposure to antipsychotics. This review examines the existing published research on the use of common typical and atypical antipsychotics in pregnancy and the implications for pregnancy and infant outcomes. RECENT FINDINGS: The majority of studies do not show associations with major malformations and antipsychotic use in pregnancy, with the possible exception of risperidone. There is concern that atypical antipsychotics may be associated with gestational diabetes. Metabolic changes during pregnancy may necessitate dose adjustments. SUMMARY: In general, it is recommended that women who need to take an antipsychotic during pregnancy continue the antipsychotic that has been most effective for symptom remission. Further study on risperidone is needed to better understand its association with malformations and it is not considered a first-line agent for use during pregnancy.
Authors: Isabella Pacchiarotti; Jordi León-Caballero; Andrea Murru; Norma Verdolini; Maria Antonietta Furio; Corinna Pancheri; Marc Valentí; Ludovic Samalin; Eva Solé Roigé; Ana González-Pinto; Jose Manuel Montes; Antonio Benabarre; Jose Manuel Crespo; Consuelo de Dios Perrino; Jose Manuel Goikolea; Luis Gutiérrez-Rojas; André F Carvalho; Eduard Vieta Journal: Eur Neuropsychopharmacol Date: 2016-08-24 Impact factor: 4.600
Authors: Clare L Taylor; Hilary K Brown; Natasha R Saunders; Lucy C Barker; Simon Chen; Eyal Cohen; Cindy-Lee Dennis; Joel G Ray; Simone N Vigod Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348